Placeholder graphic Placeholder graphic

You are here: Home > Research > Researcher Profiles

H. Shaw Warren, MD

print page content

Pediatrics/Pediatric Infectious Disease

Summary of Research

My laboratory is interested in the pathogenesis and treatment of serious bacterial infections, sepsis, and induced secondary complications such as respiratory distress syndrome (ARDS) and acute renal failure (ARF). Because sepsis is associated with overwhelming stimulation of the innate immune response with tissue damage, we are especially interested in the interactions of the bacterial cell wall with the host and its secondary inflammatory consequences. An additional recent interest is the composition of host and microbial proteins present in the CSF during infection. Projects at the moment include:

  1. Study of the components of bacterial cell walls that signal through Toll-like receptors
  2. Study of the down regulation of inflammation seen in critical illness
  3. Study of serum proteins responsible for the marked resistance of rodents to bacterial toxins.
  4. Study of the cerebral spinal fluid proteome in infection

Selected References

  1. Warren HS. Strategies for treating sepsis. New Eng. J. Med. 1997; 336: 952-953. Editorial.
  2. Ge Y, Ezzell RM, Warren HS. Localization of endotoxin in the rat intestinal epithelium. J. of Infect. Dis. 2000: 182;873-881.
  3. Hellman J, Loiselle PM, Zanzot EM, Allaire JE, Tehan MM, Boyle LA, Kurnick JT, Warren HS. Release of Gram-negative outer membrane proteins into human serum and septic rat blood and their interactions with immunoglobulin in antiserum to heat-killed Escherichia coli J5. J. Infect. Dis. 2000: 181; 1034-1043.
  4. Cross AS, Opal SM, Warren HS, Palardy JE, Buffum K, Parejo NA, Bhattacharjee AK. Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide-group B meningococcal outer membrane proteincomplex vaccine protects immunocompromised animals from experimental Klebsiella and Pseudomonas sepsis. J. Infect. Dis. 2001;183:1079-1086
  5. Hellman J, Roberts JD, Tehan MM, Allaire J, Warren HS. Bacterial peptidoglycan-associated lipoprotein is released into the bloodstream in Gram-negative sepsis and causes inflammation and death in mice. J Biol Chem. 2002 Apr 19;277(16):14274-80.
  6. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. New Eng. J. Med. 2002; 347:1027-1030 (Sounding Board)
  7. Warren HS, Matyal R, Allaire JE, Yarmush D, Loiselle P, Hellman J, Paton BG, Fink MP. Protective efficacy of CAP18106-138-IgG in sepsis J. Infect. Dis. 2003:188;1382-1393
  8. Liang, MD, Bagchi, A, Warren HS, Tehan MM, Trigilio JA, Beasley-Topliffe L, Tesini B, Lazzaroni J-C, Fenton M, Hellman J. Bacterial Peptidoglycan-Associated Lipoprotein: a potent Toll-like Receptor 2 Agonist that is shed into serum and is synergistic with LPS. J. Infect Disease 2005; 191:939-948.
  9. Tracey KJ, Warren HS. Human genetics. An inflammatory issue Nature, 2004 May 6;429(6987):35-7.

Contact Information

Phone: 617-726-5774
E-mail: swarren1@partners.org